Emergent BioSolutions Inc. (NYSE:EBS) Director Kathryn C. Zoon Sells 1,173 Shares

Emergent BioSolutions Inc. (NYSE:EBSGet Rating) Director Kathryn C. Zoon sold 1,173 shares of the company’s stock in a transaction on Thursday, June 9th. The stock was sold at an average price of $31.52, for a total transaction of $36,972.96. Following the transaction, the director now owns 19,654 shares in the company, valued at approximately $619,494.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of EBS stock traded down $1.58 on Monday, hitting $28.33. The stock had a trading volume of 644,845 shares, compared to its average volume of 685,609. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of 10.28 and a beta of 0.98. The business has a 50 day moving average of $35.19 and a 200 day moving average of $40.85. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.42 and a quick ratio of 2.81. Emergent BioSolutions Inc. has a 12-month low of $27.61 and a 12-month high of $68.03.

Emergent BioSolutions (NYSE:EBSGet Rating) last posted its quarterly earnings results on Thursday, April 28th. The biopharmaceutical company reported $0.18 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.06). The company had revenue of $307.50 million for the quarter, compared to the consensus estimate of $282.54 million. Emergent BioSolutions had a net margin of 8.96% and a return on equity of 16.05%. Emergent BioSolutions’s quarterly revenue was down 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.53 EPS. As a group, research analysts expect that Emergent BioSolutions Inc. will post 1.02 earnings per share for the current fiscal year.

Several research analysts have weighed in on the stock. Cowen lowered their price objective on shares of Emergent BioSolutions from $40.00 to $30.00 in a report on Friday, April 29th. StockNews.com downgraded shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Saturday, May 7th. Chardan Capital lowered their target price on shares of Emergent BioSolutions from $75.00 to $65.00 in a report on Friday, April 29th. Cowen lowered their target price on shares of Emergent BioSolutions from $40.00 to $30.00 in a report on Friday, April 29th. Finally, Wells Fargo & Company lowered their target price on shares of Emergent BioSolutions from $46.00 to $38.00 in a report on Wednesday, May 4th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Emergent BioSolutions currently has a consensus rating of “Hold” and an average target price of $49.17.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. boosted its position in Emergent BioSolutions by 38.6% during the fourth quarter. BlackRock Inc. now owns 8,076,901 shares of the biopharmaceutical company’s stock worth $351,104,000 after purchasing an additional 2,249,296 shares during the period. D. E. Shaw & Co. Inc. boosted its position in Emergent BioSolutions by 1,413.9% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 945,338 shares of the biopharmaceutical company’s stock worth $41,093,000 after purchasing an additional 882,893 shares during the period. State Street Corp boosted its position in Emergent BioSolutions by 26.1% during the fourth quarter. State Street Corp now owns 3,032,727 shares of the biopharmaceutical company’s stock worth $131,833,000 after purchasing an additional 628,137 shares during the period. Norges Bank bought a new position in Emergent BioSolutions during the fourth quarter worth about $18,535,000. Finally, Millennium Management LLC boosted its position in Emergent BioSolutions by 5,127.4% during the fourth quarter. Millennium Management LLC now owns 400,368 shares of the biopharmaceutical company’s stock worth $17,404,000 after purchasing an additional 392,709 shares during the period. Institutional investors own 86.02% of the company’s stock.

About Emergent BioSolutions (Get Rating)

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.

Featured Articles

Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.